Founded in 2014, 鹍远生物 positions itself as a leader in methylation detection technology and offers end-to-end products for risk assessment, early screening/diagnosis, therapy guidance and recurrence monitoring. Its product portfolio includes China-origin blood multi-gene methylation colorectal early‑screening product 常艾克® and the PanSeer® ctDNA methylation pan‑cancer screening technology. PanSeer® has been validated in large population cohorts and the company launched the “福声计划” in 2021 with Fudan University and 11 top hospitals to prospectively enroll over 60,000 people across multiple Chinese regions. The company aims to commercialize PanSeer® (targeted by end of 2023) and to expand registration, production, commercialization and international market presence including the U.S. market. Recent financing is intended to further expand the tumor early‑screening R&D pipeline and accelerate commercial and regulatory progress.

Total raised

$45M

Funding rounds

1

Latest round

Series B

Latest activity

Jun 2022